PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-18.65%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
44.07%
G&A change of 44.07% versus flat Biotechnology overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
473.10%
Other expenses change of 473.10% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
6.92%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.99%. Jim Chanos would check for waste.
6.92%
Total costs growth exceeding 1.5x Biotechnology median of 2.15%. Jim Chanos would check for waste.
No Data
No Data available this quarter, please select a different quarter.
473.10%
D&A change of 473.10% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
73.55%
EBITDA change of 73.55% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-6.92%
Operating income decline while Biotechnology median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
163.21%
Other expenses change of 163.21% versus flat Biotechnology. Walter Schloss would verify control.
121.05%
Income change of 121.05% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
121.05%
Income change of 121.05% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
121.15%
EPS change of 121.15% versus flat Biotechnology. Walter Schloss would verify quality.
115.11%
Diluted EPS change of 115.11% versus flat Biotechnology. Walter Schloss would verify quality.
2.25%
Share count change of 2.25% versus stable Biotechnology. Walter Schloss would verify approach.
42.15%
Diluted share change of 42.15% versus stable Biotechnology. Walter Schloss would verify approach.